Systematic review and meta-analysis of additional Yupingfeng powder combined with western medicine treatment at stable period of chronic obstructive pulmonary disease

• 作者: Dao-Wen Yang Hong-Bo Zhang Hong-Chun Zhang Jian-She Fan Li-Chao Sun Si-Dan Long Yun-Ru Chen
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2020,（23）
• 所属期刊栏目: Original article
• 页码范围: 49-55
• 页数: 7页
• 语种: 英文

摘要

Objective: To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD). Method: Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base, were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019. Two researchers independently screened for, selected studies according to the inclusion and exclusion criteria and extracted data. Methodological quality was evaluated using the Cochrane Risk of Bias tool. Meta-analysis was performed using Revman 5.3 software. Results: Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed. The total sample size was 1511. The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26, 95％CI(0.18,0.37)], FEV1 percentage of the estimated value [MD=4.61, 95％CI(2.43,6.79)], 6MWD[MD=43.90, 95％CI(29.48,58.32)] and patient's immunity IgA[MD=0.25, 95％CI(0.17,0.34)] and can mitigate cough effectively[MD=-0.34, 95％CI(-0.46,-0.23)]. Conclusion: Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy, lung function, immune function and have less adverse events. As most of the included studies in this systematic evaluation had poor quality, the evidence to support conclusion was weak, so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.